We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
InVivo Therapeutics Holdings Corp. (NVIV) announced today that the company has been approved by the U.S. Food and Drug Administration (FDA) for a supplementary research equipment exemption (IDE).